Piperine In The Prevention Of The Decreased Tamoxifen Sensitivity In MCF-7 Breast Cancer Cell Line

6/19/2018 12:00:00 AM

---

Authors:Sandy Vitria Kurniawan, Lies Sugiarti, Septelia Inawati Wanandi, Melva Louisa

Publication date: June 2018

International Journal of Applied Pharmaceutics

Volume:  10 (special issue 1), 335-338

Link:https://www.researchgate.net/publication/329813174_PIPERINE_IN_THE_PREVENTION_OF_THE_DECREASED_TAMOXIFEN_SENSITIVITY_IN_MCF-7_BREAST_CANCER_CELL_LINE

 

 

ABSTRACT

 

Objective: This study was designed to analyze the role of piperine in modulating P-glycoprotein mRNA expression when added in combination with tamoxifen to breast cancer cells in culture.

 

Methods: MCF-7 breast cancer cells were treated with 1 µM tamoxifen with or without piperine (12.5, 25, or 50 µM) or verapamil 50 µM (P-glycoprotein inhibitor positive control) for up to 12 days. We assessed the cell viability and isolated total RNA from them. We quantified P-glycoprotein expressions using quantitative reverse transcription polymerase chain reaction.

 

Results: Administration of various doses of piperine decreased MCF-7 breast cancer cell viability. Piperine, when given in combination with tamoxifen, decreased the expression of P-glycoprotein mRNA in cells compared with the expression in cells treated with tamoxifen only. The effects were shown to be dose dependent.

 

Conclusion: Piperine prevents the development of breast cancer cell tamoxifen resistance, probably through its inhibition of P-glycoprotein expression.

 

Keywords: P-glycoprotein,

Piperine, Tamoxifen.